Viatris shares are trading lower after the company and Mapi Pharma received a Complete Response Letter from the FDA regarding its NDA for GA Depot 40mg.
Portfolio Pulse from Benzinga Newsdesk
Viatris and Mapi Pharma received a Complete Response Letter from the FDA for their NDA for GA Depot 40mg, causing Viatris shares to trade lower.
March 11, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viatris shares are trading lower following the FDA's Complete Response Letter for the NDA of GA Depot 40mg, developed in collaboration with Mapi Pharma.
The FDA's Complete Response Letter is a significant regulatory setback for Viatris and its collaboration with Mapi Pharma on GA Depot 40mg. This news directly impacts Viatris's stock as it raises concerns about the potential delay or need for additional data, which could affect the company's revenue projections and growth strategy in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100